# Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation

Study · id `cardio:ct-nct04111419` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04111419](<https://clinicaltrials.gov/study/NCT04111419>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04111419

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT04111419. Randomized; no masking; primary purpose treatment. Start 2020-07-01 (actual); primary completion 2026-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT04111419, source copy `cardio:ctgov-nct04111419-2025-08-13`, retrieved 2026-10-26)
- Started: 2020-07-01 (actual) (ClinicalTrials.gov record NCT04111419, source copy `cardio:ctgov-nct04111419-2025-08-13`, retrieved 2026-10-26)
- Primary completion: 2026-09-30 (anticipated) (ClinicalTrials.gov record NCT04111419, source copy `cardio:ctgov-nct04111419-2025-08-13`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT04111419, source copy `cardio:ctgov-nct04111419-2025-08-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04111419, source copy `cardio:ctgov-nct04111419-2025-08-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04111419-2025-08-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation
- Condition: Atrial Fibrillation
- Condition: Hypertension
- Intervention (Drug): Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET
- Intervention (Drug): Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET
- Intervention (Drug): Allisartan Isoproxil
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)

## Provenance

Content hash: 659eef0c17f39f6fdad1424efe925bdf8ebbec0f1033c79c0a5797f86e66c772
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
